Core Viewpoint - CytoMed Therapeutics Limited has successfully completed the acquisition of allogeneic gamma delta T cell technology (TCB-002) from TC BioPharm Limited, enhancing its capabilities in developing affordable cell-based immunotherapies for cancer treatment [1][2] Group 1: Acquisition Details - The acquisition of TCB-002 complements CytoMed's strategy to establish a non-viral allogeneic gamma delta T cell immunotherapy platform for treating cancer and autoimmune diseases [2] - TCB-002 has completed a Phase I clinical trial in Europe and received orphan drug designation from the U.S. FDA for treating Acute Myeloid Leukemia [2] Group 2: Strategic Collaborations - CytoMed is in advanced discussions with potential partners to enhance and repurpose TCB-002 for cancer treatment applications in China and India, focusing on a new manufacturing method that does not require living cells [3] - This non-cell-based approach allows for easier scaling within China due to strict regulations on biological materials, providing advantages in treatment speed, accessibility, and cost-effectiveness compared to autologous therapies [3] Group 3: Regulatory Environment - The new initiative to establish a presence in China replaces previous agreements with Chinese parties and aligns with new regulations from the State Council aimed at liberalizing the clinical use of cellular products [4] - State Council Decree No. 818 establishes a regulatory pathway for cell therapies in China, allowing for a streamlined process from clinical research to clinical application, which is beneficial for CytoMed's allogeneic gamma delta T cell platform [5] Group 4: Current Developments - CytoMed's gamma delta T cell technology has been granted a patent by the China National Intellectual Property Administration, and the company is conducting a Phase I clinical trial in Singapore [6] - The completion of the acquisition is not expected to have an immediate material financial impact on the company [7] Group 5: Company Background - CytoMed, incorporated in 2018, focuses on developing novel cell-based allogeneic immunotherapies for various cancers, inspired by the success of CAR-T therapies [8]